Checkpoint kinase inhibitor synergizes with DNA-damaging agents in G1 checkpoint-defective neuroblastoma. - Wikidata - awgldk - TriplyDB

Checkpoint kinase inhibitor synergizes with DNA-damaging agents in G1 checkpoint-defective neuroblastoma.

Checkpoint kinase inhibitor synergizes with DNA-damaging agents in G1 checkpoint-defective neuroblastoma.

http://www.wikidata.org/entity/Q39620511

about

Therapeutic targets for neuroblastomas.Molecularly targeted therapies in non-small-cell lung cancer annual update 2014 Role of checkpoint kinase 1 (Chk1) in the mechanisms of resistance to histone deacetylase inhibitors Potentiation of the novel topoisomerase I inhibitor indenoisoquinoline LMP-400 by the cell checkpoint and Chk1-Chk2 inhibitor AZD7762.Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma.MicroRNA-497 impairs the growth of chemoresistant neuroblastoma cells by targeting cell cycle, survival and vascular permeability genes.CASZ1 inhibits cell cycle progression in neuroblastoma by restoring pRb activity Pharmacodynamic modeling of cell cycle and apoptotic effects of gemcitabine on pancreatic adenocarcinoma cells.Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53.Targeting the ATR-CHK1 Axis in Cancer Therapy Checkpoint kinase 1 expression is an adverse prognostic marker and therapeutic target in MYC-driven medulloblastoma CDKN2A/p16 deletion in head and neck cancer cells is associated with Cdk2 activation, replication stress, and vulnerability to Chk1 inhibition.

P2860

Q34560877-1A1AF451-6948-4ECB-868D-A0DE8EFC4A3F Q35136424-376538B9-412F-4EE1-BE16-2F808FC1F34F Q35621123-03D5BC39-E804-4C96-9593-7C5937DF56D9 Q35782905-847B2384-5972-4CFB-AEF4-CA609EB22727 Q36545022-6541B895-89B2-4EC2-ABB7-ABEAEE464130 Q36962575-E100C129-B3CC-4A02-9537-1C9C1354E366 Q37126173-BE718BEF-A1FC-4B9D-A4DE-2B2BF1AF8B92 Q37182951-95CE7DBF-581C-444C-BF8F-0211F93FD9BA Q37638784-963755C6-150D-4115-A735-762E6CB536D5 Q38817102-9FD8C778-30EB-416F-9B48-967EC8EB2445 Q42324653-F7EE9300-F94D-4C0E-A202-8E75D880E91D Q48573026-39D7A81C-62E5-4A97-8262-83B8300CA54D

P2860

Checkpoint kinase inhibitor synergizes with DNA-damaging agents in G1 checkpoint-defective neuroblastoma.

http://www.wikidata.org/entity/Q39620511

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Checkpoint kinase inhibitor sy ...... point-defective neuroblastoma.

@en

Checkpoint kinase inhibitor sy ...... point-defective neuroblastoma.

@nl

type

label

Checkpoint kinase inhibitor sy ...... point-defective neuroblastoma.

@en

Checkpoint kinase inhibitor sy ...... point-defective neuroblastoma.

@nl

prefLabel

Checkpoint kinase inhibitor sy ...... point-defective neuroblastoma.

@en

Checkpoint kinase inhibitor sy ...... point-defective neuroblastoma.

@nl

P1433

Q39620511-C6BEE411-C6BF-4653-82D5-BD673D4022B5

P1476

Q39620511-80D11828-0973-42E0-8B21-464EB166028B

P2093

Q39620511-4F1BAC91-B034-47A3-86B2-D3FCEA08F8AA

Q39620511-624F9E6D-24DF-4DB0-8660-DE4EBCB3562C

Q39620511-6D874501-6667-4EE5-AF7D-02D781C5292C

Q39620511-810EBA74-FF1A-4006-B631-9CB6789B7E97

Q39620511-B0572C5F-B5B9-4CDB-B62F-C9C2D11FE595

Q39620511-F661C5DF-9058-47FC-8CAA-0029DDADA915

P2860

Q39620511-0436F771-DB9E-430E-A0D1-BFE59051B89A

Q39620511-245F5D5B-9B3A-4AD2-B56B-24DA1F005DE0

Q39620511-3B5B0FA2-C1A5-4D04-8098-6A3521BA50B9

Q39620511-47344C62-0A63-4CA8-BD8B-2A382A58C81B

Q39620511-4F91DCB6-7B19-421B-AB0C-86A42FB3B516

Q39620511-53EB7E17-8A46-412B-81D4-1FD7E9153176

Q39620511-5652087C-21C2-4E42-AD9B-6C8093DB32DF

Q39620511-5980AA19-CFBD-42DF-A28C-AFD8B93C98E3

Q39620511-5FCCD875-9509-40D7-BF42-20CF84793C4A

Q39620511-6159813C-C594-4A99-8799-56A7E1B35F98

P304

Q39620511-0ACA71D4-0334-4EC9-9690-3BC5C5FBAD2E

P31

Q39620511-8FE654F2-FAF1-411B-B84B-1288F4EEB45D

P356

Q39620511-D65A5C78-D448-4636-B2C7-C8BFAF8985C6

P433

Q39620511-B0837F97-9978-4F90-B78D-4BFC8C3454F5

P478

Q39620511-11FE50DD-DCE0-45C7-B437-9159B00904E0

P577

Q39620511-21DA7BAA-E563-435A-B415-7DBD42D503DB

P5875

Q39620511-D3600551-F7EB-470E-8EF5-19468E4D8A8A

P698

Q39620511-37BF54AA-3378-4928-B42A-CF7C07DE2D3B

P356

P1433

International Journal of Cancer

P1476

Checkpoint kinase inhibitor sy ...... point-defective neuroblastoma.

@en

P2093

Hoa Tran

http://www.w3.org/2001/XMLSchema#string

Hong Xu

http://www.w3.org/2001/XMLSchema#string

Irene Y Cheung

http://www.w3.org/2001/XMLSchema#string

Nai-Kong V Cheung

http://www.w3.org/2001/XMLSchema#string

Xiao X Wei

http://www.w3.org/2001/XMLSchema#string

Xiaoni Gao

http://www.w3.org/2001/XMLSchema#string

P2860

Surfing the p53 network

Cell cycle kinases as therapeutic targets for cancer

The DNA damage response: ten years after

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma.

New insights into checkpoint kinase 1 in the DNA damage response signaling network.

Two molecularly distinct G(2)/M checkpoints are induced by ionizing irradiation

Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma.

Chk1 requirement for high global rates of replication fork progression during normal vertebrate S phase.

Long-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study.

P304

1953-1962

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.25842

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

129

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49680268

http://www.w3.org/2001/XMLSchema#string

P698

21154747

http://www.w3.org/2001/XMLSchema#string